Study of Bicalutamide 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions
The objective of this study is to compare the rate and extent of absorption of bicalutamide 50 mg tablets (test) versus Casodex® (reference) administered as 1 x 50 mg tablet under fed conditions.
|Study Design:||Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Parallel Assignment
Masking: Open Label
|Official Title:||Randomized, 1-Way, Parallel, Bioequivalence Study of Bicalutamide 50 mg Tablets and Casodex® Administered as 1 x 50 mg Tablet in Healthy Subjects Under Fed Conditions|
- Cmax - Maximum Observed Concentration [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
- AUC0-72 - Area under the concentration-time curve from time zero to 72 hours post dose [ Time Frame: Blood samples collected over 72 hour period ] [ Designated as safety issue: No ]
|Study Start Date:||September 2003|
|Study Completion Date:||September 2003|
|Primary Completion Date:||September 2003 (Final data collection date for primary outcome measure)|
Bicalutamide 50 mg Tablet
50 mg Tablet
Active Comparator: Casodex®
Casodex® 50 mg Tablet
50 mg Tablet
This will be a single center, bioequivalence, open-label, randomized 1-way parallel study.
According to the BA/BE guidances, a parallel study is acceptable for drugs with a long half-life.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00972855
|Sainte-Foy, Quebec, Canada, G1V 2K8|
|Principal Investigator:||Richard Larouche, MD||Anapharm|